{Reference Type}: Journal Article
{Title}: Use of an antiemetic to shorten the length of labor in nulliparous women, exploring a potential role of an old drug: A randomized controlled trial.
{Author}: Ellaithy M;Rasheed S;Shafik A;Abees S;
{Journal}: Int J Gynaecol Obstet
{Volume}: 148
{Issue}: 1
{Year}: Jan 2020
{Factor}: 4.447
{DOI}: 10.1002/ijgo.12998
{Abstract}: <B>OBJECTIVE: </B>To assess whether metoclopramide is effective in shortening the duration of the first stage of labor in primiparous women.<BR><B>METHODS: </B>The present randomized, double-blind, placebo-controlled trial was conducted at King Faisal Hospital, Saudi Arabia (between July 30, 2013, and September 1, 2016), and sequentially recruited young nulliparous women admitted in spontaneous active labor with or without ruptured membranes. Eligible participants were randomly assigned to receive a slow intravenous injection of either metoclopramide or placebo and consistently managed according to the local institutional intrapartum protocol and received identical monitoring and supportive care. The primary outcome was the cervical dilatation rate.<BR><B>RESULTS: </B>Fifty-nine women were included in the metoclopramide group and 52 in the placebo group. The first stage of labor was significantly shorter in the metoclopramide group (203 minutes vs 230 minutes in the placebo group, P=0.019), with a faster cervical dilatation rate (2.4 ± 0.4 cm/h vs 1.9 ± 0.5 cm/h in the placebo group, P<0.001) and shorter interval from treatment administration until full cervical dilatation. There was a significantly higher probability of faster delivery among women who were treated with metoclopramide (log-rank test, χ2 =5.997, P=0.014).<BR><B>CONCLUSIONS: </B>Metoclopramide safely reduced the duration of the first stage of labor and was not associated with major maternal or neonatal adverse outcomes. CLINICALTRIALS.GOV: NCT01937234.